According to the World Health Organization (WHO) defi nition, counterfeit medicines form part of a broader category of pharmaceutical products which do not meet quality standards in force, with the difference that they are deliberately and fraudulently mislabelled with respect to their real composition and/or source. Counterfeit medicines may be both branded and generic and may contain genuine constituents in a fake packaging, or wrong ingredients, or inactive ingredients, or an incorrect quantity of the active substance (1, 2) . The use of such medicines poses a health risk in that the intended effect of a medicinal product is not achieved, which may result in unexpected adverse effects, anaphylaxis, resistance to medicinal product, or other health problems (3) (4) (5) . Most industrialised countries with an effi cient system and market surveillance regulation have a low percentage of such products, mostly below 1 %, whereas in many countries of Africa and parts of Asia and Latin America the market share of such products exceeds 30 % (6) (7) (8) (9) (10) . Counterfeit medicines in the European Union are mostly the "lifestyle" drugs, including medicinal products for erectile dysfunction and obesity (11) . Apart from these, there are fake medicines for oncological, cardiac, psychiatric, and infectious diseases (12) (13) (14) . This trend in pharmaceutical crime may further rise, because the driving force behind it are high gains and high sales accompanied by utter disregard for the health of patients, which makes it a global problem (15) (16) (17) (18) .
In Croatia, no cases of counterfeit medicines have been detected so far in licensed pharmacies or in wholesale chains. But on the illegal drug market 34 samples have been seized. The products were classifi ed in three groups, the fi rst of which included products authorised for marketing in Croatia, the second comprised products without marketing authorisation, and the third products which are not medicines but rather medical devices or dietary supplements ( Figure 1 ). The fi rst and the second group consisted of 26 samples indicated for the treatment of erectile dysfunction, declared to contain active substances sildenafi l, tadalafi l, or vardenafi l ( Figure 2 ).
The purpose of this study was to determine the safety of samples identifi ed as sildenafi l and taldalafi l in view of possible counterfeiting.
MATERIALS AND METHODS
The samples were submitted to the Agency as the regulatory authority by Zagreb Police Department. High performance liquid chromatography (HPLC) was used to separate sildenafi l and tadalafi l from their potential degradation products, process-related impurities, and formulation constituents according to manufacturer instructions. Sildenafi l and tadalafi l were quantifi ed by comparing chromatographic peak areas of sample solutions with reference standard solutions. The following reference substances were used to prepare reference solutions: sildenafi l citrate; Pfi zer (USA), lot 0015-QSC-23 and tadalafi l; Lilly (USA); lot 991085.
To determine active substances in tablets of the illegal products, we used a liquid chromatograph equipped with a column oven, a variable wavelength ultraviolet absorption detector, and a sample injection system. Sildenafi l and tadalafi l content in test samples was calculated as percentage of declared content of sildenafi l and tadalafi l per tablet.
Chromatographic conditions for sildenafi l and tadalafi l identifi cation are given in Table 1 .
RESULTS AND DISCUSSION
If a fi nished medicinal product is licensed for marketing in Croatia and the manufacturer is based outside Croatia, the distributor or the importer shall apply to the Agency for quality verification for every imported batch or for Agency's consent if its quality has been tested in the European Union. A comparison with samples licensed for marketing in Croatia (sildenafi l 50 mg tablets, sildenafi l 100 mg tablets, tadalafi l 20 mg tablets, vardenafi l 10 mg tablets, vardenafi l 20 mg tablets) showed that samples submitted by the police were not authorised for marketing in Croatia, and were most likely intended for distribution in countries other than Croatia or for an illegal drug market.
Medicinal products lacking marketing authorisation for Croatia may be imported only with a special import license issued by the Agency. Since its foundation, the
Figure 1 Medicines and other products from illegal supply

Figure 2 Medicinal products from illegal supply according to their active pharmaceutical ingredients
Agency has never issued a special import licence for any of the reference medicinal products (C/Finegra 100 mg tablets 1 , Sildofi l 100 mg tablets 2 , Cobra 100 mg tablets 3 , Kamagra TM 100 mg tablets 4 , Novagra forte 100 mg tablets 5 , Vega 100 mg tablets 6 , Venegra 100 mg tablets 7 , Virecta 100 mg tablets 8 , Apcalis plus 20 mg tablets 9 ). Other submitted samples not identifi ed as medicines or medical devices are not within Agency's scope of responsibility ( Figure 1 ). One can not discard the possibility that some of these products are classifi ed as medicines in other countries. This group of products includes Femi-X 10 tablets, manufactured by Danish Pharmaceutical Industries Ltd., that have been authorised for marketing in Croatia as a dietary supplement intended to increase libido in women. Other products, Wollust Tropfen, Erotic Fluid, and Original Inverma Yohimbinum 11 were manufactured by Inverma Chemie, Germany. According to the declaration, these products are intended to increase potency and contain ginseng extract and yohimbine at very low concentrations otherwise typical of homeopathic products.
During authorisation of authentic medicines, the Agency for Medicinal Products and Medical Devices approved the manufacturer's specifi cations which were used in the Agency for testing the fi rst group of drugs. The tests included verifi cation and quantifi cation of 1 Manufacturer is not specifi ed 2 Future Pharmaceuticals 3 MB C 4 Aajanta Pharma Limited 5 Brown & Burk (UK) Ltd. 6 Manufacturer is not specifi ed 7 Anvaxx Laboratory, USA 8 EVA Pharma 9 MS Pharma 10 Femi-X A/S 11 Inverma Arzneimittel the active substance against reference substance using high-performance liquid chromatography (HPLC).
The Agency does not possess any manufacturers' documentation or analytical instructions for medicines lacking marketing authorisation in Croatia. As, according to the declaration, the medicines from the second group contained the same active substance as the authorised medicinal products, we used the same methods as for licensed fi nished medicinal products to verify and quantify them. As not all submitted batches had enough samples to meet manufacturer's instructions for analysis, we tested only two samples per batch, and the results were not statistically analysed.
Sildenafi l samples were prepared in accordance with the procedure for Viagra ® tablets manufactured by Pfi zer. Two samples containing one tablet each were tested from each batch (Table 2, Figure 3 ).
Tadalafil samples, again two per batch, were prepared by combining three individual tablets in a 250 mL volumetric fl ask and processing them in accordance with the procedure for Cialis tablets manufactured by Lilly (Table 2, Figure 4) .
The presence of the active substance has been confi rmed in all tested samples, so in qualitative terms all samples conformed to declarations. Table 2 and Figure 5 show the quantitative composition in the tested samples of the fi rst and second group of medicines. 
Figure 6 Deviation from active substance content in tablet samples
Figure 3 A typical chromatogram of sildenafi l sample and reference standard
Figure 4 A typical chromatogram of tadalafi l sample and reference standard
Figure 5 Test results of sildenafi l and tadalafi l tablets
CONCLUSION
Even if test results fall within acceptable margins, one can safely verify the authenticity of a medicine only after receiving manufacturer's opinion based on complete batch data. Manufacturers alone possess complete data and in case of suspicion can run a series of additional target tests in their laboratories, including additional tests for purity profi les of active substances, excipients used in the finished drug product, type and material of primary and secondary packaging, or the quality and credibility of printing. These additional tests can make it easier and quicker to see whether a drug is authentic or fake; indeed, they are sometimes the only means to do this. Suffi ciently discriminating analytical techniques are also needed, 
